Compare Organon Pharma Indonesia Tbk. (SCPI) vs Venteny Fortuna International Tbk. (VTNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon Pharma Indonesia Tbk. vs Venteny Fortuna International Tbk. — how do they compare? Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B), while Venteny Fortuna International Tbk. trades at Rp72 (market cap 476.15B, 21.68M 24h volume). The key difference: Venteny Fortuna International Tbk. is far larger — about 4.6× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| SCPI | VTNY | |
|---|---|---|
Market Cap | 104.4B | 476.15B |
Volume | — | 21.68M |
Lot | — | 216.81K |
Turnover | — | 1.59B |
Average Price | — | 73.22 |
Value | — | 1.59B |
Indicative Equilibrium Price | — | 72 |
Indicative Equilibrium Volume | — | 4.89K |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →About Venteny Fortuna International Tbk.
PT Venteny Fortuna International Tbk (the Entity) was established based on Notarial Deed No. 7,dated January 29, 2021 of Anastasia Chandra, S.H., M.Kn., Notary in Tangerang. The Entity started its commercial operations in 2021. PT Venteny Fortuna International Tbk is the parent entity, whereas Junichiro Waide is the ultimate beneficial owner.
Read more on VTNY →
